EQS-Adhoc: BB Biotech AG publishes its 2023 annual report

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Report/Dividend BB Biotech AG publishes its 2023 annual report 16-Feb-2024 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR February 16, 2024 Annual report of BB Biotech AG as at December 31, 2023  BB Biotech AG publishes its 2023 annual report BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in. In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond market rally and encouraged equity markets further – but led to a noticeable devaluation of the USD, particularly relative to the CHF. Additionally, the year witnessed an uptick in takeover activities. The biotech sector made strong gains as the year closed. BB Biotech achieved significant gains in the fourth quarter. For the full year, BB Biotech’s total share return was ‑18.1% in CHF and -15.2% in EUR, substantially behind the portfolio performance of -7.4% in CHF, -1.3% in EUR and +1.8% in USD. The net loss for BB Biotech in 2023 was CHF 207 mn. As already announced on January 19, 2024, BB Biotech will propose a dividend of CHF 2.00 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2023. This marks a continuation of the dividend policy of the previous years. BB Biotech’s annual report 2023 is available under report.bbbiotech.ch/2023/en resp. www.bbbiotech.com For further information: Investor Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. [phone] Dr. Silvia Siegfried-Schanz, [e-mail] Maria-Grazia Alderuccio, [e-mail] Claude Mikkelsen, [e-mail] Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. [phone] Tanja Chicherio, [e-mail] TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. [phone] Thomas Egger, [e-mail] www.bbbiotech.com Company profile   BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.  End of Inside Information 16-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	BB BIOTECH AG
	Schwertstrasse 6
	8200 Schaffhausen
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.bbbiotech.ch
ISIN:	CH0038389992
WKN:	A0NFN3
Listed:	Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID:	1838425

End of Announcement	EQS News Service

1838425  16-Feb-2024 CET/CEST